Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Gold Coast Investment Conference 2017
32 slides from Prescient Therapeutics's conference presentation, Jun 22, 2017
Slide 1: Developing Novel Targeted Therapies to Beat Cancer
For personal use only DEVELOPING NOVEL TARGETED THERAPIES TO BEAT CANCER Prescient Therapeutics Limited (ASX: PTX) Gold Coast Investment Conference June 2017
Slide 2: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts b
Slide 3: Company Overview
COMPANY For personal use only OVERVIEW 3 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only 2 DRUGS » IMMINENT CATALYSTS » FUNDING IN PLACE » UNDISCOVERED VALUE • 2 targeted therapies with impeccable scientific pedigree • Multiple shots on goal with Akt and Ras pathway inhibitors in multiple trials • One of deepest clinical pipelines on the ASX »
Slide 5: Corporate Snapshot
CORPORATE SNAPSHOT For personal use only KEY METRICS ASX Ticker PTX Market Capitalisation1 A$11.2 M (US$8.5 M) Total Issued Capital 211.3 M shares Cash Position2 A$8.7 M (US$6.4 M) Options 57.8 M Top 20 Own 52% Share Price1 A$0.052 (US$0.04) 6 month turnover1 40.7 M shares; A$3.4 M (US$2.6 M) SHARE
Slide 6: Deep, Clinical Stage Product Pipeline
DEEP, CLINICAL STAGE PRODUCT PIPELINE For personal use only • PTX-200 currently in three clinical trials, recruitment currently on hold pending SAE response • Advancing PTX-100 in rare hematological cancers - a transformative opportunity DISCOVERY SCREENING PRE-CLINICAL PHASE 1 PHASE 1B PHASE 2 PHAS
Slide 7: Continuing to Deliver Meaningful Progress
CONTINUING TO DELIVER MEANINGFUL PROGRESS For personal use only RECENT PROGRESS PLANNED UPCOMING ACTIVITIES PTX-200 PTX-100 AML: Phase 1b study initiated at Moffitt and Yale; first cohort successfully completed • Commence activities in new hematology indication Breast Cancer: Phase 1b completed
Slide 8: Investment Decision Funnel for Any Biotech
INVESTMENT DECISION FUNNEL FOR ANY BIOTECH For personal use only Is the drug in a clinical trial, or still pre-clinical? Both drugs clinical stage Is the trial conducted to US FDA standard? All INDs (under US FDA) Do the indications make clinical & Targeting unmet/poorly met medical commercial
Slide 9: Drugs Don't Develop Themselves!
DRUGS DON’T DEVELOP THEMSELVES! PTX DEVELOPMENT TEAM WITH BENCH TO BEDSIDE SUCCESS For personal use only Proven success from discovery and clinical development, through to FDA approvals • Professor and Chair, Department of Drug Discovery - Moffitt Cancer Center Said Sebti, PhD • Co-inventor of PTX-1
Slide 10: World Class Centers & Collaborations
WORLD CLASS CENTERS & COLLABORATIONS For personal use only CONNECTICUT KANSAS NEW YORK FLORIDA PREVIOUS CLINICAL TRIALS CONDUCTED AT: 10 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 11: How Our Drugs Work: Molecular Switches
HOW OUR DRUGS WORK: “MOLECULAR SWITCHES” For personal use only Akt & Ras are growth molecules found in cells – when they are stuck “on”, they send constant signals to the cancer cell to grow PTX’s drugs block the Akt & Ras growth pathways, PTX-100 switching the growth signals off and causing the can
Slide 12: PTX-200 Novel Akt Inhibition
PTX-200 For personal use only NOVEL AKT INHIBITION AML Breast cancer Ovarian cancer 12 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 13: Akt Is a Master Switch for Cellular Growth & Survival
AKT IS A MASTER SWITCH FOR CELLULAR GROWTH & SURVIVAL For personal use only 13 ERSAHIN, T. ET AL; MOL. BIOSYST., 2015,11, 1946-1954
Slide 14: PTX-200: Novel Akt Inhibition via PH Domain Binding
PTX-200: NOVEL AKT INHIBITION VIA PH DOMAIN BINDING For personal use only • Akt must be bound to the plasma membrane to be activated • PTX-200 prevents Akt binding to plasma membrane by binding to the PH domain, thereby inactivating Akt • This approach has an advantage over other Akt attempts, which
Slide 15: Acute Myeloid Leukemia Overview
ACUTE MYELOID LEUKEMIA OVERVIEW For personal use only • AML is a type of cancer that affects the blood and bone marrow » Patient cannot produce normal blood cells » Blood cells cannot function properly nor fight disease • Progresses very quickly; 5 year survival only 25% • More common in adults over
Slide 16: PTX-200 in AML – Overview
PTX-200 IN AML – OVERVIEW For personal use only • Akt is highly relevant in AML (high pAkt = inferior survival) • PTX-200 address 72% of AML mutations • Like other recent successful strategies in AML, PTX-200 is a targeted therapy complementing a “backbone” of standard chemotherapy (cytarabine) • PT
Slide 17: Spectacular Story of Celator Pharmaceuticals
SPECTACULAR STORY OF CELATOR PHARMACEUTICALS • Celator (NASDAQ: CPXX) soared to ~$780M valuation on positive Phase 3 data in AML For personal use only (naïve/newly diagnosed secondary AML) 31 March 2016 • Jazz Pharmaceuticals announced US$1.5B cash takeover of CPXX on 31 May 2016 • Reformulation of
Slide 18: Phase 1b AML Trial Underway
PHASE 1B AML TRIAL UNDERWAY For personal use only • Phase 1 results with PTX-200 (monotherapy) very encouraging • Now PTX-200 + cytarabine in refractory or relapsed acute leukemia » 15 -18 patients » 3+3 design, single arm » Up to 4 dose levels of PTX-200 starting at 25 mg/m2 (days 1, 8, 15) » Cytar
Slide 19: Breast Cancer Overview
BREAST CANCER OVERVIEW For personal use only • Breast cancer market currently US$10 B; due to double by 2023 • Most breast cancer drug sales are for HER2+ cancers, but this only represents ~20% of all breast cancers • By contrast, HER2- has “flown under the radar” of drug developers, due to high pro
Slide 20: Phase 1b Breast Cancer Trial Completed
PHASE 1B BREAST CANCER TRIAL COMPLETED • For personal use only PTX-200 in combination with paclitaxel, followed by AC (doxorubicin & cyclophosphamide) • Patients with metastatic and locally advanced HER2- breast cancer » Albert Einstein College of Medicine Montefiore Medical Center and the H. Lee Mo
Slide 21: Ovarian Cancer Overview
OVARIAN CANCER OVERVIEW For personal use only • One of the most common cancers in women - increasing with an ageing population • Due to reach US$1.7 B by 2019 » Market size currently constrained by old generic drugs that just aren’t good enough • Standard of care has not changed in decades (often ge
Slide 22: Phase 1b Ovarian Cancer Trial
PHASE 1B OVARIAN CANCER TRIAL For personal use only • Significant need for new products to treat platinum-resistant ovarian cancer • Testing PTX-200 plus carboplatin in patients with platinum resistant ovarian cancer • PTX-200 already proven overcome cisplatin resistance and synergize with cisplatin
Slide 23: PTX-100 First in Class Inhibitor of Ras Pathway
PTX-100 For personal use only FIRST IN CLASS INHIBITOR OF RAS PATHWAY Phase 1 in solid tumors completed; Now pursuing a transformative opportunity in rare blood cancers 23 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 24: Ras Pathway Is an Important but Elusive Target
RAS PATHWAY IS AN IMPORTANT BUT ELUSIVE TARGET For personal use only GROWTH FACTOR • Ras mutated in 30% of all human cancers and 90% RECEPTOR TYR KINASE in certain cancers » A staggering 3 million new cancers diagnosed worldwide Grb2 SoS each year with Ras mutations Ras FGTI • Mutant Ras tumors are
Slide 25: Big Opportunity in Rare Hematological Niche
BIG OPPORTUNITY IN RARE HEMATOLOGICAL NICHE For personal use only • Recent research has revealed that a certain mutation (mutation X) is a key driver in certain haematological cancers • Some of these conditions are characterized by: » Being rare » Having poor prognoses with short median survival » V
Slide 26: PTX-100 the Most Advanced Drug Targeting Mutation in Question
PTX-100 THE MOST ADVANCED DRUG TARGETING MUTATION IN QUESTION • Only 12 oncology drugs in development in For personal use only PTX-100 1 addressing mutation X » No others are in the clinic NO. OF DRUGS IN DEVELOPMENT » None are in hematology indications » PTX-100 is the most advanced, with Phase 1 A
Slide 27: Rare Diseases Can Transform Smaller Companies
RARE DISEASES CAN TRANSFORM SMALLER COMPANIES For personal use only • Rare diseases (<200,000 patients in US) can present big opportunities for smaller companies • Markets may be too small for some Big Pharma, but are big enough to transform smaller companies » e.g. Folotyn (Spectrum Pharmaceuticals
Slide 28: Value Proposition
VALUE For personal use only PROPOSITION 28 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Slide 29: PTX Operates in Areas with Rich Deal Activity
PTX OPERATES IN AREAS WITH RICH DEAL ACTIVITY For personal use only Deals1 since Jan 2016 Median deal size # transactions (US$M) AML 44 143 Ovarian cancer 36 234 Breast cancer2 30 255 Rare diseases (oncology)3 972 154 1. Deals defined as mergers, acquisitions, licenses and strategic alliances 2. Bre
Slide 30: Significant Valuation Arbitrage
SIGNIFICANT VALUATION ARBITRAGE For personal use only Significant valuation arbitrage …Arbitrage against US AML peers is even against comparable ASX peers… 1,000 more pronounced 900 800 400 700 350 MARKET CAP US$M 600 300 MARKET CAP A$M 500 250 ASX peer average A$181M 400 200 300 US AML peer average
Slide 31: Investment Highlights
INVESTMENT HIGHLIGHTS For personal use only 2 DRUGS » IMMINENT CATALYSTS » FUNDING IN PLACE » UNDISCOVERED VALUE • 2 targeted therapies with impeccable scientific pedigree • Multiple shots on goal with Akt and Ras pathway inhibitors in multiple trials • One of deepest clinical pipelines on the ASX »
Slide 32: Contact
For personal use only CONTACT Steven Yatomi-Clarke e: steven@ptxtherapeutics.com CEO & Managing Director t: +61 417 601 440 Prescient Therapeutics Limited w: ptxtherapeutics.com 32 TARGETED THERAPIES YIELDING A DEEP CLINICAL PIPELINE
Prescient Therapeutics — Gold Coast Investment Conference 2017 on 6ix